Phosphorylated neurofilament heavy chain: A biomarker of survival for C9ORF72‐associated amyotrophic lateral sclerosis

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Annals of Neurology

• Publication date

  2017-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ana.24980PMID 28628244PMCID PMC5676468
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis

  2017cited by this paper
• Poly(Gp) Proteins Are A Useful Pharmacodynamic Marker For C9Orf72-Associated Amyotrophic Lateral Sclerosis

  2017cited by this paper
• Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs.

  2016cited by this paper
• Attenuated traumatic axonal injury and improved functional outcome after traumatic brain injury in mice lacking Sarm1.

  2016cited by this paper
• Phosphorylated neurofilament heavy chain levels in paired plasma and CSF of amyotrophic lateral sclerosis.

  2016cited by this paper
• Fluid-Based Biomarkers for Amyotrophic Lateral Sclerosis

  2016cited by this paper
• Longitudinal imaging in C9orf72 mutation carriers: Relationship to phenotype

  2016cited by this paper
• Assessment of a multiple biomarker panel for diagnosis of amyotrophic lateral sclerosis

  2016cited by this paper
• Comparative analysis of C9orf72 and sporadic disease in an ALS clinic population

  2016cited by this paper
• Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis

  2015cited by this paper
• Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients

  2015cited by this paper
• Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD/ALS.

  2014cited by this paper
• Author Manuscript

  2013cited by this paper
• Analysis of the C9orf72 Gene in Patients with Amyotrophic Lateral Sclerosis in Spain and Different Populations Worldwide

  2013cited by this paper
• RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention.

  2013cited by this paper
• Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study

  2012cited by this paper
• Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis

  2012cited by this paper
• Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS.

  2011cited by this paper
• Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS

  2011cited by this paper
• A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD.

  2011cited by this paper
• Classification of primary progressive aphasia and its variants

  2011cited by this paper
• Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia.

  2011cited by this paper
• Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis

  2009cited by this paper
• Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF‐H) in blood of ALS model rodents and ALS patients: evaluation of blood pNF‐H as a potential ALS biomarker

  2009cited by this paper
• Relaxing the rule of ten events per variable in logistic and Cox regression.

  2007cited by this paper
• Axonal damage markers in cerebrospinal fluid are increased in ALS

  2006cited by this paper
• El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis

  2000cited by this paper
• Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria.

  1999cited by this paper
• Frontotemporal lobar degeneration

  1998cited by this paper

• Current potential biomarkers for Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis: review of literature

  2026influential citation
• Frontiers in neurodegeneration: Biomolecular triggers, diagnostic biomarkers, and smart nanotherapeutics

  2026cites this paper
• Antisense-Oligonukleotide zur Therapie der amyotrophen Lateralsklerose

  2025cites this paper
• Comparative analysis of cerebrospinal fluid neurofilament medium, light and heavy chain in neurodegenerative diseases using an in-house assay for the detection of neurofilament medium chain

  2025cites this paper
• Retinoid X Receptor Alpha Overexpression Protects Retinal Ganglion Cells and Modulates Inflammatory Response in Experimental Glaucoma.

  2025cites this paper
• Molecular impact of antisense oligonucleotide therapy in C9orf72-associated ALS.

  2025cites this paper
• Trial of Two-Drug Regimen for ALS Shows Benefit for Some Patients

  2025cites this paper
• Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial.

  2025cites this paper
• Global research trends in biomarkers, therapeutic targets, and drugs for amyotrophic lateral sclerosis: a bibliometric and visualization analysis

  2025cites this paper
• FVC-DiP correlates with neurofilament light chain levels in serum and cerebrospinal fluid in patients with ALS

  2025cites this paper
• Phosphorylated neurofilament heavy chain (pNfH) concentration in cerebrospinal fluid predicts overall disease aggressiveness (D50) in amyotrophic lateral sclerosis

  2025cites this paper
• ALS plasma biomarkers reveal neurofilament and pTau correlate with disease onset and progression

  2025cites this paper
• Amyotrophic lateral sclerosis caused by hexanucleotide repeat expansions in C9orf72: from genetics to therapeutics.

  2025cites this paper
• Biomarkers in ALS trials: from discovery to clinical utility

  2025cites this paper
• Neurofilaments as biomarkers in neurological disorders — towards clinical application

  2024cites this paper
• Blood-Based Biomarkers in Frontotemporal Dementia: A Narrative Review

  2024cites this paper
• A Review of Biomarkers of Amyotrophic Lateral Sclerosis: A Pathophysiologic Approach

  2024cites this paper
• Neurofilaments in neurologic disease.

  2024cites this paper
• Neurofilaments in Sporadic and Familial Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis

  2024cites this paper
• Fluid biomarkers for amyotrophic lateral sclerosis: a review

  2024cites this paper
• Neurodegenerative biomarkers outperform neuroinflammatory biomarkers in amyotrophic lateral sclerosis

  2023cites this paper
• Theme 10 - Disease Stratification and Phenotyping of Patients

  2023cites this paper
• Comparison of CSF and plasma NfL and pNfH for Alzheimer’s disease diagnosis: a memory clinic study

  2023cites this paper
• Biomarkers in amyotrophic lateral sclerosis: current status and future prospects

  2023cites this paper
• Immunological drivers of amyotrophic lateral sclerosis

  2023cites this paper
• Advances in molecular pathology, diagnosis, and treatment of amyotrophic lateral sclerosis

  2023cites this paper
• Roadmap for C9ORF72 in Frontotemporal Dementia and Amyotrophic Lateral Sclerosis: Report on the C9ORF72 FTD/ALS Summit

  2023cites this paper
• Studies of Genetic and Proteomic Risk Factors of Amyotrophic Lateral Sclerosis Inspire Biomarker Development and Gene Therapy

  2023cites this paper
• Proteomic analysis of human serum Extracellular Vesicles reveals early diagnostic markers for Amyotrophic Lateral Sclerosis

  2023cites this paper
• Charting the Next Road Map for CSF Biomarkers in Alzheimer’s Disease and Related Dementias

  2023cites this paper
• Serum Neurofilaments in Motor Neuron Disease and Their Utility in Differentiating ALS, PMA and PLS

  2023cites this paper
• Differences in Cerebral Glucose Metabolism in ALS Patients with and without C9orf72 and SOD1 Mutations

  2023cites this paper
• Clinical and genetic features of amyotrophic lateral sclerosis patients with C9orf72 mutations

  2023cites this paper
• TDP-43 Proteinopathy Specific Biomarker Development

  2023cites this paper
• A unified classification approach rating clinical utility of protein biomarkers across neurologic diseases

  2023cites this paper
• Structural and microstructural neuroimaging signature of C9orf72-associated ALS: A multiparametric MRI study

  2023cites this paper
• Biofluid biomarkers of amyotrophic lateral sclerosis

  2022cites this paper
• Inhibiting mitochondrial fission rescues degeneration in hereditary spastic paraplegia neurons.

  2022cites this paper
• Ketamine Mitigates Neurobehavioral Deficits in a Canine Model of Hypothermic Circulatory Arrest.

  2022cites this paper
• Biomarkers and molecular mechanisms of Amyotrophic Lateral Sclerosis

  2022cites this paper
• Neurofilaments in neurologic disorders and beyond.

  2022cites this paper
• Genetic factors for survival in amyotrophic lateral sclerosis: an integrated approach combining a systematic review, pairwise and network meta-analysis

  2022cites this paper
• Phosphorylated Neurofilament Heavy Chain: A Potential Diagnostic Biomarker in Amyotrophic Lateral Sclerosis.

  2022cites this paper
• Cerebrospinal fluid biomarkers of disease activity and progression in amyotrophic lateral sclerosis

  2022cites this paper
• Lipidomic traits of plasma and cerebrospinal fluid in amyotrophic lateral sclerosis correlate with disease progression

  2021cites this paper
• Fluid Biomarkers of Frontotemporal Lobar Degeneration.

  2021cites this paper
• Current application of neurofilaments in amyotrophic lateral sclerosis and future perspectives

  2021cites this paper
• Synaptopathy Mechanisms in ALS Caused by C9orf72 Repeat Expansion

  2021cites this paper
• Urine levels of the polyglutamine ataxin-3 protein are elevated in patients with spinocerebellar ataxia type 3

  2021cites this paper
• Comparative diagnosis interest of NfL and pNfH in CSF and plasma in a context of FTD–ALS spectrum

  2021cites this paper
• Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS

  2021cites this paper
• Circulating Biomarkers in Neuromuscular Disorders: What Is Known, What Is New

  2021cites this paper
• Plasma and CSF Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: A Cross-Sectional and Longitudinal Study

  2021cites this paper
• Advancing mechanistic understanding and biomarker development in amyotrophic lateral sclerosis

  2021cites this paper
• Neurofilaments can differentiate ALS subgroups and ALS from common diagnostic mimics

  2021cites this paper
• Biomarkers for C9orf7-ALS in Symptomatic and Pre-symptomatic Patients: State-of-the-art in the New Era of Clinical Trials

  2021cites this paper
• Predictors of survival in patients with amyotrophic lateral sclerosis: A large meta-analysis

  2021cites this paper
• Cross-sectional and longitudinal measures of chitinase proteins in amyotrophic lateral sclerosis and expression of CHI3L1 in activated astrocytes

  2020cites this paper
• PROSPECTIVE BLOOD-BASED BIOMARKERS OF NEURODEGENERATION

  2020cites this paper
• Extracellular vesicles – propagators of neuropathology and sources of potential biomarkers and therapeutics for neurodegenerative diseases

  2020cites this paper
• Fluid biomarkers in frontotemporal dementia: past, present and future

  2020cites this paper
• Toward allele-specific targeting therapy and pharmacodynamic marker for spinocerebellar ataxia type 3

  2020cites this paper
• Neurofilaments in motor neuron disorders: towards promising diagnostic and prognostic biomarkers

  2020cites this paper
• Insights into disease mechanisms and potential therapeutics for C9orf72-related amyotrophic lateral sclerosis/frontotemporal dementia.

  2020cites this paper
• Transcriptome alterations in myotonic dystrophy frontal cortex

  2020cites this paper
• Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis.

  2020cites this paper
• A multi-center study of neurofilament assay reliability and inter-laboratory variability

  2020cites this paper
• Longitudinal biomarkers in amyotrophic lateral sclerosis

  2020cites this paper
• Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS

  2020cites this paper
• Cerebrospinal fluid MFG-E8 as a promising biomarker of amyotrophic lateral sclerosis

  2020cites this paper
• Serum phosphorylated neurofilament heavy-chain levels reflect phenotypic heterogeneity and are an independent predictor of survival in motor neuron disease

  2020influential citation
• Multiplexed Phosphoproteomic Study of Brain in Patients with Alzheimer's Disease and Age-Matched Cognitively Healthy Controls

  2020cites this paper
• Neurofilaments in disease: what do we know?

  2020cites this paper
• Biomarkers of Blood–Brain Barrier Dysfunction

  2019cites this paper
• CSF angiogenin levels in amyotrophic lateral Sclerosis-Frontotemporal dementia spectrum

  2019cites this paper
• Survival and Prognostic Factors in C9orf72 Repeat Expansion Carriers: A Systematic Review and Meta-analysis.

  2019cites this paper
• Validation of Serum Neurofilaments as Prognostic & Potential Pharmacodynamic Biomarkers for ALS

  2019cites this paper
• Diagnostic and Prognostic Role of Blood and Cerebrospinal Fluid and Blood Neurofilaments in Amyotrophic Lateral Sclerosis: A Review of the Literature

  2019cites this paper
• Early onset but long survival and other prognostic factors in Chinese sporadic amyotrophic lateral sclerosis.

  2019cites this paper
• Neurochemical biomarkers in amyotrophic lateral sclerosis.

  2019cites this paper
• Neuronal damage and neuroinflammation markers in patients with autoimmune encephalitis and multiple sclerosis

  2019cites this paper
• Correlations between serum and CSF pNfH levels in ALS, FTD and controls: a comparison of three analytical approaches

  2019cites this paper
• Analysis of neurofilament concentration in healthy adult horses and utility in the diagnosis of equine protozoal myeloencephalitis and equine motor neuron disease.

  2019cites this paper
• A Systematic Review of Suggested Molecular Strata, Biomarkers and Their Tissue Sources in ALS

  2019cites this paper
• Psychiatric Symptoms in Amyotrophic Lateral Sclerosis: Beyond a Motor Neuron Disorder

  2019cites this paper
• Diagnostic and Prognostic Performance of Neurofilaments in ALS

  2019cites this paper
• Predictors of survival and progression in behavioural variant frontotemporal dementia

  2019cites this paper
• Biomarkers for diseases with TDP-43 pathology.

  2019cites this paper
• A motor neuron strategy to save time and energy in neurodegeneration: adaptive protein stoichiometry

  2018cites this paper
• Biomarkers for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Associated With Hexanucleotide Expansion Mutations in C9orf72

  2018cites this paper
• [A prognostic biomarker in amyotrophic lateral sclerosis].

  2018cites this paper
• Pathological hydrogen peroxide triggers the fibrillization of wild-type SOD1 via sulfenic acid modification of Cys-111

  2018cites this paper
• Current state of Alzheimer’s fluid biomarkers

  2018cites this paper
• Cerebrospinal Fluid Neurofilaments May Discriminate Upper Motor Neuron Syndromes: A Pilot Study

  2018cites this paper
• Multi-Omics for Biomarker Discovery and Target Validation in Biofluids for Amyotrophic Lateral Sclerosis Diagnosis

  2018cites this paper
• Neurofilaments as biomarkers in neurological disorders

  2018cites this paper
• Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis

  2018cites this paper
• Paraneoplastic neuronal intermediate filament autoimmunity

  2018cites this paper
• Overexpression of MAP2 and NF-H Associated with Dendritic Pathology in the Spinal Cord of Mice Infected with Rabies Virus

  2018cites this paper
• Taxonomy Meets Neurology, the Case of Amyotrophic Lateral Sclerosis

  2018cites this paper